Clinigence Holdings Inc (NUTX)
NASDAQ:NUTX
Want to see NUTX full AI Analyst Report?
NUTX Stock Chart & Stats
$184.11
-$1.17(-3.51%)
At close: 4:00 PM EST
$184.11
-$1.17(-3.51%)
Day’s Range― - ―
52-Week Range$77.21 - $193.07
Previous CloseN/A
Volume3.28K
Average Volume (3M)152.06K
Market Cap
$993.67M
Enterprise Value$910.50M
Total Cash (Recent Filing)$207.35M
Total Debt (Recent Filing)$349.09M
Price to Earnings (P/E)10.0
Beta2.08
Next Earnings
Aug 06, 2026EPS Estimate
4.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)13.44
Shares Outstanding6,881,339
10 Day Avg. Volume140,770
30 Day Avg. Volume152,055
Financial Highlights & Ratios
PEG Ratio1.68
Price to Book (P/B)3.18
Price to Sales (P/S)1.20
P/FCF Ratio4.26
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue1.03
Enterprise Value/Gross Profit2.18
Enterprise Value/Ebitda3.12
Forecast
1Y Price Target
$205.00Price Target Upside11.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)21.02
Revenue Forecast (FY)$883.02M
Bulls Say, Bears Say
Bulls Say
Robust Revenue GrowthSustained double‑digit top‑line expansion (TTM ~54%, 2025 ~82%) indicates structural demand for the platform and services. Durable revenue momentum supports reinvestment in hospitals, technology and population‑health scale, improving long‑term operating leverage and contestability.
Strong Cash GenerationMaterial and sustained OCF and FCF in the TTM period suggest high earnings quality and internal funding capacity. Reliable cash conversion enables capital investments, share buybacks and deleveraging without immediate reliance on external financing, strengthening financial durability.
Improved Leverage And ReturnsMeaningful deleveraging from prior years (debt/equity to ~0.73x) and strong recent ROE (~24%) reduce solvency risk and enhance balance‑sheet flexibility. A stronger capital base lowers refinancing sensitivity and supports growth projects and M&A over the medium term.
Bears Say
Gross Margin CompressionA ~13.5pp drop in gross margin reflects sustained facility cost and arbitration expense pressure. If higher facility-level costs and supply/labor inflation persist, margin recovery may be slow, constraining operating leverage and cash flow durability despite revenue growth.
IDR/arbitration Accounting VolatilityThe asymmetric arbitration accounting (full cost recognition vs phased revenue) produces recurring timing volatility in EBITDA and margins. This structural mismatch complicates earnings predictability, working‑capital management and comparability with peers over multi‑quarter periods.
Rising Accounts Receivable / Working CapitalA sizable increase in AR elevates working‑capital needs and indicates collection/timing risk tied to IDR and payer processes. Persistent AR growth could pressure free cash flow conversion and require greater liquidity buffers or external funding during downturns.
Clinigence Holdings News
NUTX FAQ
What was Clinigence Holdings Inc’s price range in the past 12 months?
Clinigence Holdings Inc lowest stock price was $77.21 and its highest was $193.07 in the past 12 months.
What is Clinigence Holdings Inc’s market cap?
Clinigence Holdings Inc’s market cap is $993.67M.
When is Clinigence Holdings Inc’s upcoming earnings report date?
Clinigence Holdings Inc’s upcoming earnings report date is Aug 06, 2026 which is in 51 days.
How were Clinigence Holdings Inc’s earnings last quarter?
Clinigence Holdings Inc released its earnings results on Apr 30, 2026. The company reported $6.52 earnings per share for the quarter, beating the consensus estimate of $3.993 by $2.527.
Is Clinigence Holdings Inc overvalued?
According to Wall Street analysts Clinigence Holdings Inc’s price is currently Undervalued.
Does Clinigence Holdings Inc pay dividends?
Clinigence Holdings Inc does not currently pay dividends.
What is Clinigence Holdings Inc’s EPS estimate?
Clinigence Holdings Inc’s EPS estimate is 4.88.
How many shares outstanding does Clinigence Holdings Inc have?
Clinigence Holdings Inc has 6,881,339 shares outstanding.
What happened to Clinigence Holdings Inc’s price movement after its last earnings report?
Clinigence Holdings Inc reported an EPS of $6.52 in its last earnings report, beating expectations of $3.993. Following the earnings report the stock price went up 17.089%.
Which hedge fund is a major shareholder of Clinigence Holdings Inc?
Currently, no hedge funds are holding shares in NUTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Clinigence Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$205.00 (11.35% Upside)
$205.00 (11.35% Upside)
Blogger Sentiment
Neutral
NUTX Sentiment 50%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $45.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.1%
Last 30 Days ▼ 2.4%
Last 30 Days ▼ 2.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.58%
12-Months-Change
Fundamentals
Return on Equity
31.39%
Trailing 12-Months
Asset Growth
25.65%
Trailing 12-Months
Company Description
Clinigence Holdings Inc
Nutex Health, Inc. functions as a technology-powered enterprise delivering healthcare services, structured into two key segments: its Hospital division and its Population Health Management division. The Hospital division is tasked with developing and overseeing various healthcare models, encompassing micro-hospitals, specialized medical centers, and hospital outpatient facilities. This segment currently owns and operates 21 locations spanning eight different states. Meanwhile, the Population Health Management division establishes and manages provider networks, such as independent physician associations. Additionally, its management services organizations furnish administrative, operational, and support assistance to its associated hospitals and physician groups. A proprietary, cloud-based technology platform within this division is crucial; it aggregates patient and provider data from multiple information systems, settings, and sources to construct a holistic view, thereby enabling more effective care delivery. The company maintains its corporate headquarters in Houston, Texas.
NUTX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed picture: operationally and strategically Nutex demonstrates strong liquidity, improved net income, positive cash flow, active share repurchases, patient satisfaction, and a clear strategy to internalize development and scale population health. However, significant margin pressure and a 21% drop in adjusted EBITDA driven by higher facility costs and timing effects from IDR/arbitration recognition temper the results. Same-hospital revenue growth was minimal and accounts receivable rose, highlighting near-term execution and working capital considerations. Regulatory and arbitration accounting dynamics introduce additional volatility. Overall, positive cash generation and strategic initiatives are balanced by meaningful margin and accounting headwinds.View all NUTX earnings summariesNUTX Stock 12 Month Forecast
Average Price Target
$205.00
▲(11.35% Upside)
Technical Analysis
HealthStream
―
Evolent Health
―
Health Catalyst
―
10x Genomics
―
Definitive Healthcare Corp
―
Ownership Overview
32.86% Insiders
6.44% Mutual Funds
11.89% Other Institutional Investors
35.77% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---